SlideShare a Scribd company logo
Diabetes Mellitus Dr. CAI Mengyin Department of Endocrinology 3 rd  Affiliated Hospital Sun Yat-sen University
[object Object],[object Object],[object Object],The official mascots  of the Beijing 2008 Olympic Games Populous country with obesity pandemic Asia countries are facing challenge from Diabetes
Economy taking-off like a rocket  with dramatic lifestyle change State “on Bicycle” Traffic jam in Beijing Coupon for food in Guangzhou One week’s food for a family in Beijing Exercise less Eat More
Prevalence rate of Diabetes Throughout the world: 150 millions ? 2% USA: 15 millions China:  9.7 % --  N Engl J Med 2010;362:1090-101. China: 1980 0.609% in 304537 Canton: 1980 0.411% in 42788
What is Diabetes Mellitus? Definition: Syndrome Metabolic disorder of multiple etiology (causes) characterized by hyperglycemia with carbohydrates, fat, and protein metabolic alterations, which result in defects in the secretion  or action of insulin, or both.
Hyperglycemia X or Metabolic Syndrome Metabolic abnormalities and by long-term  complications involving  eyes, kidneys, nerves, and blood vessels   Acute complications: diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma. homogenous Heterogeneous
Genetic factors Environmental factors Chinese  population  9% Monogenic Polygenic Aging Lifestyle Infections Diabetes Type I <10% Type II >90% Etiology and Development
Defect of β Cell in Insulin Secretion & Action
Non - diabetes Pre - diabetes Diabetes IGT/IFG Fasting plasma  glucose Insulin  requirement Insulin  production <6.1mmol/L >7.0 mmol/L
Derangements are due to relative or absolute insulin deficiency and glucagon excessiveness. Normally, it is a rise in the molar ratio of glucagon to insulin which leads to diabetic decompensation .  Why does metabolic derangement  happen?
 
Spectrum of Diabetes Mellitus Insulin receptor gene mutations (<1%) Insulin gene mutations (<1%) Mitochondrial gene mutations (2%) Type 2 (70%) Type 1 (10%) LADA (10-12% ?) MODY (2-4% ?)
1  yr 10  yr 21  yr 32  yr 45  yr 60  yr Age at diagnosis TYPE1 TYPE2 MODY LADA MIDD DIDMOAD ? Variable Faces of Diabetes Mellitus
Type 1 diabetes mellitus Usually onset before age of 40.  In USA, peak incidence is around 14 years old.  Onset of symptoms may be abrupt, with thirst, excessive urination, increased appetite and weight loss developing over a several-day period. In some cases, the disease is heralded by the appearance of DKA during and intercurrent illness or following surgery.
Type 2 Diabetes Mellitus Usually  starts in middle age or older.  Symptoms begin more gradually than in type 1 diabetes, and diagnosis is frequently made when an asymptomatic person is found to have an elevated plasma glucose on routine lab. Exam..
Type 1 vs. Type 2 Type 1 Type 2 Age of onset Childhood, young adult Adulthood, elder people Body cells Responsive to insulin Resistant to insulin Autoantibodies Positive Negative Body fatness Low to average High Endogenous insulin Little or none Normal or too much Pancreatic function Beta cells not functional Beta cell normal Severity of symptoms Severe; liable to DKA Mild; few or none,  not liable to DKA Insulin shots? Yes, indispensable Not during early and middle stage Drugs? Not solely Yes
 
Maturity-onset diabetes of the young (MODY) 45 33 22 12 16 17 10 INS OHA OHA DIET DIET DIET INS Classical MODY-criteria: 1.  Two patients diagnosed    with diabetes before the    age 25 years. 2.  Autosomal dominant    inheritance of diabetes   (   3 generations) Note: Yellow figures indicating ages at on-set.
History of MODY genes MODY2 GCK MODY1 Linkage to chr20 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 MODY2 Linkage to chr7 MODY3 Linkage to chr12 MODY3 HNF-1  MODY1 HNF-4  MODY5 HNF-1  MODY4 IPF1
 
Severe insulin resistance syndrome Insulin signaling associated mutation Lypodystrophy syndrome linked mutation Other gene IR gene AKT2 gene BSCL FPLD MAD CaR gene AGPAT2 gene Seipin gene LMNA PPARγ gene  LMNA ZMPSTE24 gene
Type A insulin resistance syndrome ,[object Object],[object Object],[object Object]
Sequencing of IR exon20 Black Arrow : P1174W Green Arrow : P1178P Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
HGPS, RD the  “most”  complicated and lethal type of laminopathies HGPS RD Hum Mol Genet, 2004, 13: 2493-2503. N Engl Med, 2008,358: 552-555.
In some other secondary identifiable condition, a diabetic syndrome can develop ,[object Object],[object Object],[object Object],[object Object],[object Object],Mechanism of Stress of Hyperglycemia ,[object Object],[object Object],[object Object]
Gestational Diabetes Mellitus ◆  Definition: Carbohydrates intolerance of variable severity with  onset or first recognition during pregnancy ◆   Screening: American Diabetic Association(ADA) Recommend screening all pregnant women  at 24-26 wks using 50g oral glucose test with 1 hour blood glucose value of 140mg or more as an indication for standard oral glucose tolerance test.  No stipulations as to the time of last meal.
Clinical manifestation   The manifestations of symptomatic diabetes mellitus vary from patient to patient.  Most often medical help is sought because of symptoms related to hyperglycemia: polyuria, polydipsia, polyphagia.
But, the first event may be an acute metabolic decompensation resulting in diabetic coma. More occasionally, the initial expression can be a degenerative complication such as neuropathy in the absence of symptomatic hyperglycemia.
Classifications of Diabetic Vascular Disease ,[object Object],[object Object]
Increased coagulability Platelet hypersensitivity Increased blood viscosity Impaired microvascular flow Increased microvascular pressure and flow Microvascular sclerosis Limitation of maximum perfusion Failure of autoregulation Raised capillary pressure Tissue damage Hypothesis for Diabetic Microangiopathy
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Background ,[object Object],[object Object],[object Object],[object Object],Preproliferative ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Proliferative ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Advanced diabetic eye disease ,[object Object],[object Object],[object Object],[object Object],Maculopathy Stages of Diabetic Retinopathy
Background Proliferative Diabetic Retinopathy
Diabetic Nephropathy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diabetic Neuropathy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Limited joint mobility Motor damage  Sensory damage  Autonomic damage Microcirculatory disease Macrovascular disease Diabetic neuropathy Diabetes ,[object Object],[object Object],[object Object],Abnormal foot posture Reduced pain and proprioception A-V shunting ,[object Object],[object Object],Increased foot pressures Reduced tissue nutrition Callus formation Ischaemia Ulceration Infection Pathways to Diabetic Foot
Foot ulceration Charcot arthropathy Diabetic Foot
Laboratory Findings ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],-  ±  +  ++  +++  ++++
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],6 8 10 12 14 16 18 20 0 10 20 30 40 50 60 control PATIENT 0.693 K (glucose)=  × 100 t  1/2
Insulin (mU/L) 30  60  90  120  150  180  210  min  T2DM Normal T1DM ,[object Object],[object Object],[object Object],[object Object]
C peptide A chain B chain ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis of Diabetes Mellitus ,[object Object],[object Object],[object Object],[object Object]
Treatment of Diabetes Mellitus Management Goals ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
LDL-c mmol/L <2.5 2.5-4.4 >4.5 ★ According to UKPDS data . Targets for Diabetic Control Good Moderate Poor FPG mmol/L 4.4-6.1 ≤ 7.0 >7.0 PBS mmol/L 4.4-8.0 ≤ 10.0 >10.0 HbA1c ★ % <6.2 6.2-8.0 >8.0 BMI Kg/m 2 M<25 F<24 M<27 F<26 M ≥ 27 F ≥ 26 T ch mmol/L <4.5 ≥ 4.5 6.0 HDL-c mmol/L >1.1 1.1-0.9 <0.9 TG mmol/L <1.5 <2.2 ≥ 2.2
Major Therapeutic Trials 1 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Major Therapeutic Trials 2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Diet
Food Pyramid ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Physical Activities ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Exercise Guidelines ※   Monitor BG before and after exercise. ※ Avoid exercise if BG >250 mg/dl, ketones present. ※   Use caution with exercise if BG>300 mg/dl, without ketones. ※   Eat CHO if BG < 100 mg/dl ※   If exercise is planned for just after a meal, consider reducing the short acting insulin that covers that meal. ※   If exercise is planned for 3-4 hours after a meal, consider reducing the long-acting insulin. ※   For unplanned exercise, consider adding carbohydrate. ※   Consume CHO before, during, or after exercise to prevent  hypoglycemia. ※   Always keep CHO foods readily available during exercise.
Oral Hypoglycemic Agents
Sulphonylureas ,[object Object],[object Object],[object Object]
Sulfonylurea Activates Insulin Secretion Small figure shows the site of action.
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Secondary Failure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Biguanides (Metformin) Mode of action: ◇ reduces hepatic glucose production ◇ decreased intestinal absorption of glucose ◇ increases peripheral utalisation of glucose in muscle & fat tissue ◇ decreased insulin requirements for glucose disposal
Precautions:   ● chronic renal or cardiac failure    ● hepatic impairment   ● elderly   ● excessive alcohol intake Side effects: ◆ gastrointestinal disturbances  ◆ metallic taste ◆ malabsorption of B12 Administer:   with or after meals
Alpha Glucosidase Inhibitor  (Acarbose) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Thiazolidinedione ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Insulin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Insulin preparations and time of reaching peak and duration
Lipoatrophy due to long term injection of ‘impure’ insulin preparations.
Novopen Inhaled insulin Insulin pump
Oral Agents + Insulin in Type 2 Diabetes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Rationale:
Diabetic Ketoacidosis Presentation Physical examination Laboratory results Polyuria, polydipsia Nausea, vomiting Diarrhea, abd. Pain Evolution for a few days Stupor or coma in Loss of skin turgor Kussmaul breathing  Acetone odor Cerebral edema PH <7.3, HCO 3  <15 Eq/L Glucose > 250 mg/dl Elevated anion gap High serum ketones High uric acid Normal osmolality
Precipitating Factors of DKA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment of DKA – IV fluid Normal saline 1 liter/hr until not orthostatic hypotensive,  then  NS at 500 ml/hr Electrolytes every 2 hrs initially, then every 4 hours Glucose <250 mg/dl, change to Dextrose with 1:4 regular insulin at 250-500 ml/hr  When anion gap normal, bicarbonate >15 mEq/L, taking PO fluid, give meal and SC insulin
Treatment of DKA – Insulin IV insulin at 5-10 u/hr in adult, 0.1 u/kg/hr in child Check glucose hourly, if no change in 2 hrs double the insulin infusion Glucose <250 mg/dl, slow insulin to 2-4 u/hr Discontinue IV insulin 2-3 hrs after SC insulin dose
Treatment of DKA – Potassium Potassium repletion if initial K is normal or low at 10-40 mEq/hr Check potassium every 2- 4 hrs Replete total body potassium stores over 2- 3 days
Treatment of DKA – Bicarbonate, Phosphorus Bicarbonate replacement if pH less than 6.90 Check phosphorus 12 hrs into treatment. Replace if < 1 mEq/L

More Related Content

What's hot

Diabetes Mellitus and its types
Diabetes Mellitus and its types Diabetes Mellitus and its types
Diabetes Mellitus and its types
Fatima Rahat
 
Diabetes mellitus an overview
Diabetes mellitus an overviewDiabetes mellitus an overview
Diabetes mellitus an overviewRuth Nwokoma
 
Diabetes mellitus type 2
Diabetes mellitus type 2Diabetes mellitus type 2
Diabetes mellitus type 2
Esther Mary Mathew
 
Diabetes mellitus
Diabetes mellitus Diabetes mellitus
Diabetes mellitus
Jyoti Gaver
 
Diabetes
DiabetesDiabetes
Type 1 diabetes mellitus
Type 1 diabetes mellitusType 1 diabetes mellitus
Type 1 diabetes mellitus
priyanka bhardwaj
 
Diabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogsDiabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogs
Abubakkar Raheel
 
Complications of Diabetes Mellitus
Complications of Diabetes MellitusComplications of Diabetes Mellitus
Complications of Diabetes Mellitus
Carmela Domocmat
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Abhra Ghosh
 
Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus  Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus Dilek Gogas Yavuz
 
Diabetes Mellitus Type 2
Diabetes Mellitus Type 2Diabetes Mellitus Type 2
Diabetes Mellitus Type 2
AdamBilski2
 
Hypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and TreatmentHypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and Treatment
Bangabandhu Sheikh Mujib Medical University
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Md Jahirul Islam Sojib
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Sara Ravi
 
Diabetes Mellitus (DM)
Diabetes Mellitus (DM)Diabetes Mellitus (DM)
Diabetes Mellitus (DM)
Abhay Rajpoot
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
Shubhrat Maheshwari
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitusReynel Dan
 
Diabetes
Diabetes Diabetes
Diabetes
Balaji Thorat
 
Complications of diabetes melitus
Complications of diabetes melitusComplications of diabetes melitus
Complications of diabetes melitus
ANILKUMAR BR
 

What's hot (20)

2. diabetes mellitus
2. diabetes mellitus2. diabetes mellitus
2. diabetes mellitus
 
Diabetes Mellitus and its types
Diabetes Mellitus and its types Diabetes Mellitus and its types
Diabetes Mellitus and its types
 
Diabetes mellitus an overview
Diabetes mellitus an overviewDiabetes mellitus an overview
Diabetes mellitus an overview
 
Diabetes mellitus type 2
Diabetes mellitus type 2Diabetes mellitus type 2
Diabetes mellitus type 2
 
Diabetes mellitus
Diabetes mellitus Diabetes mellitus
Diabetes mellitus
 
Diabetes
DiabetesDiabetes
Diabetes
 
Type 1 diabetes mellitus
Type 1 diabetes mellitusType 1 diabetes mellitus
Type 1 diabetes mellitus
 
Diabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogsDiabetes Mellitus and Insuline analogs
Diabetes Mellitus and Insuline analogs
 
Complications of Diabetes Mellitus
Complications of Diabetes MellitusComplications of Diabetes Mellitus
Complications of Diabetes Mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus  Diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus
 
Diabetes Mellitus Type 2
Diabetes Mellitus Type 2Diabetes Mellitus Type 2
Diabetes Mellitus Type 2
 
Hypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and TreatmentHypoglycemia- Assessment and Treatment
Hypoglycemia- Assessment and Treatment
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes Mellitus (DM)
Diabetes Mellitus (DM)Diabetes Mellitus (DM)
Diabetes Mellitus (DM)
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes
Diabetes Diabetes
Diabetes
 
Complications of diabetes melitus
Complications of diabetes melitusComplications of diabetes melitus
Complications of diabetes melitus
 

Viewers also liked

19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosisinternalmed
 
11 heart failure
11 heart failure11 heart failure
11 heart failureinternalmed
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
23 renal disease
23 renal disease23 renal disease
23 renal diseaseinternalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13internalmed
 
4 pleural effusions
4 pleural effusions4 pleural effusions
4 pleural effusionsinternalmed
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhouinternalmed
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathyinternalmed
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeinternalmed
 
4 bronchiectasis
4 bronchiectasis4 bronchiectasis
4 bronchiectasisinternalmed
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitisinternalmed
 

Viewers also liked (20)

19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
 
11 heart failure
11 heart failure11 heart failure
11 heart failure
 
10 hypertension
10 hypertension10 hypertension
10 hypertension
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
Anemia
AnemiaAnemia
Anemia
 
9 asthma
9 asthma9 asthma
9 asthma
 
15 ie
15 ie15 ie
15 ie
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13
 
4 pleural effusions
4 pleural effusions4 pleural effusions
4 pleural effusions
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhou
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathy
 
1 introduction
1 introduction1 introduction
1 introduction
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
 
4 bronchiectasis
4 bronchiectasis4 bronchiectasis
4 bronchiectasis
 
6 lungcancer
6 lungcancer6 lungcancer
6 lungcancer
 
7 cor pulmonale
7 cor pulmonale7 cor pulmonale
7 cor pulmonale
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitis
 

Similar to C:\documents and settings\administrator\桌面\35 ndiabetes mellitus

Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementMedicineAndFamily
 
DIABETES MELLITUS by dr aftab ahmed
DIABETES  MELLITUS by dr aftab ahmedDIABETES  MELLITUS by dr aftab ahmed
DIABETES MELLITUS by dr aftab ahmed
aaiman46
 
Diabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmedDiabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmedaaiman46
 
diabetes-mellitus3143.pptx
diabetes-mellitus3143.pptxdiabetes-mellitus3143.pptx
diabetes-mellitus3143.pptx
MubashirHussan2
 
Diabetic retinopathy
Diabetic retinopathyDiabetic retinopathy
Diabetic retinopathy
Anjali Maheshwari
 
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
ueda2015
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes MellitusKhalid
 
Diabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral ManifestationsDiabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral Manifestationskhateeb9
 
Diabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptxDiabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptx
Jos University Teaching Hospital
 
Diabetes mellitus
Diabetes mellitus Diabetes mellitus
Diabetes mellitus
زياد الزهراني
 
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONSRECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
SANJAY YADAV
 
Diabetes new final compiled
Diabetes new final compiledDiabetes new final compiled
Diabetes new final compiledChandrika Verma
 
Ueda2015 diabetic nephropathy dr.ashraf talaat
Ueda2015 diabetic  nephropathy dr.ashraf talaatUeda2015 diabetic  nephropathy dr.ashraf talaat
Ueda2015 diabetic nephropathy dr.ashraf talaatueda2015
 
Surgery in diabetes patients Dr nesar Ahmad
Surgery in diabetes patients   Dr nesar AhmadSurgery in diabetes patients   Dr nesar Ahmad
Surgery in diabetes patients Dr nesar Ahmad
Student
 
Presentation final montanya
Presentation final montanyaPresentation final montanya
Presentation final montanya
Sociedad Española de Cardiología
 
Pathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitusPathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitus
niva niva
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
Sadananda Reddy
 
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase MethodDetermination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Zoldylck
 
Biomarkers of diabetic retinopathy
Biomarkers of diabetic retinopathyBiomarkers of diabetic retinopathy
Biomarkers of diabetic retinopathy
rx_sonali
 

Similar to C:\documents and settings\administrator\桌面\35 ndiabetes mellitus (20)

Diabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental managementDiabetes Mellitus patients in dental management
Diabetes Mellitus patients in dental management
 
DIABETES MELLITUS by dr aftab ahmed
DIABETES  MELLITUS by dr aftab ahmedDIABETES  MELLITUS by dr aftab ahmed
DIABETES MELLITUS by dr aftab ahmed
 
Diabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmedDiabetes melitus by dr aftab ahmed
Diabetes melitus by dr aftab ahmed
 
diabetes-mellitus3143.pptx
diabetes-mellitus3143.pptxdiabetes-mellitus3143.pptx
diabetes-mellitus3143.pptx
 
Diabetic retinopathy
Diabetic retinopathyDiabetic retinopathy
Diabetic retinopathy
 
Dm 1 1
Dm 1 1Dm 1 1
Dm 1 1
 
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
Ueda 2016 2-pathophysiology ,classification &amp; diagnosis of diabetes - kha...
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Diabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral ManifestationsDiabetes Mellitus & Its Oral Manifestations
Diabetes Mellitus & Its Oral Manifestations
 
Diabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptxDiabetes Mellitus Type 2 - Pathology.pptx
Diabetes Mellitus Type 2 - Pathology.pptx
 
Diabetes mellitus
Diabetes mellitus Diabetes mellitus
Diabetes mellitus
 
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONSRECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
 
Diabetes new final compiled
Diabetes new final compiledDiabetes new final compiled
Diabetes new final compiled
 
Ueda2015 diabetic nephropathy dr.ashraf talaat
Ueda2015 diabetic  nephropathy dr.ashraf talaatUeda2015 diabetic  nephropathy dr.ashraf talaat
Ueda2015 diabetic nephropathy dr.ashraf talaat
 
Surgery in diabetes patients Dr nesar Ahmad
Surgery in diabetes patients   Dr nesar AhmadSurgery in diabetes patients   Dr nesar Ahmad
Surgery in diabetes patients Dr nesar Ahmad
 
Presentation final montanya
Presentation final montanyaPresentation final montanya
Presentation final montanya
 
Pathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitusPathophysiology of diabetes mellitus
Pathophysiology of diabetes mellitus
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase MethodDetermination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
Determination of Blood Glucose Using Glusose Oxidase-Peroxidase Method
 
Biomarkers of diabetic retinopathy
Biomarkers of diabetic retinopathyBiomarkers of diabetic retinopathy
Biomarkers of diabetic retinopathy
 

More from internalmed

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular diseaseinternalmed
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitisinternalmed
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial diseaseinternalmed
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gaointernalmed
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 
13 respiratory failure
13 respiratory failure13 respiratory failure
13 respiratory failureinternalmed
 

More from internalmed (13)

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitis
 
18 peptic ulcer
18 peptic ulcer18 peptic ulcer
18 peptic ulcer
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial disease
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gao
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 
Anemia
AnemiaAnemia
Anemia
 
13 respiratory failure
13 respiratory failure13 respiratory failure
13 respiratory failure
 

Recently uploaded

Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
Atul Kumar Singh
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
TechSoup
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
GeoBlogs
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 

Recently uploaded (20)

Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
Language Across the Curriculm LAC B.Ed.
Language Across the  Curriculm LAC B.Ed.Language Across the  Curriculm LAC B.Ed.
Language Across the Curriculm LAC B.Ed.
 
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup   New Member Orientation and Q&A (May 2024).pdfWelcome to TechSoup   New Member Orientation and Q&A (May 2024).pdf
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdf
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 

C:\documents and settings\administrator\桌面\35 ndiabetes mellitus

  • 1. Diabetes Mellitus Dr. CAI Mengyin Department of Endocrinology 3 rd Affiliated Hospital Sun Yat-sen University
  • 2.
  • 3. Economy taking-off like a rocket with dramatic lifestyle change State “on Bicycle” Traffic jam in Beijing Coupon for food in Guangzhou One week’s food for a family in Beijing Exercise less Eat More
  • 4. Prevalence rate of Diabetes Throughout the world: 150 millions ? 2% USA: 15 millions China: 9.7 % -- N Engl J Med 2010;362:1090-101. China: 1980 0.609% in 304537 Canton: 1980 0.411% in 42788
  • 5. What is Diabetes Mellitus? Definition: Syndrome Metabolic disorder of multiple etiology (causes) characterized by hyperglycemia with carbohydrates, fat, and protein metabolic alterations, which result in defects in the secretion or action of insulin, or both.
  • 6. Hyperglycemia X or Metabolic Syndrome Metabolic abnormalities and by long-term complications involving eyes, kidneys, nerves, and blood vessels Acute complications: diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma. homogenous Heterogeneous
  • 7. Genetic factors Environmental factors Chinese population  9% Monogenic Polygenic Aging Lifestyle Infections Diabetes Type I <10% Type II >90% Etiology and Development
  • 8. Defect of β Cell in Insulin Secretion & Action
  • 9. Non - diabetes Pre - diabetes Diabetes IGT/IFG Fasting plasma glucose Insulin requirement Insulin production <6.1mmol/L >7.0 mmol/L
  • 10. Derangements are due to relative or absolute insulin deficiency and glucagon excessiveness. Normally, it is a rise in the molar ratio of glucagon to insulin which leads to diabetic decompensation . Why does metabolic derangement happen?
  • 11.  
  • 12. Spectrum of Diabetes Mellitus Insulin receptor gene mutations (<1%) Insulin gene mutations (<1%) Mitochondrial gene mutations (2%) Type 2 (70%) Type 1 (10%) LADA (10-12% ?) MODY (2-4% ?)
  • 13. 1 yr 10 yr 21 yr 32 yr 45 yr 60 yr Age at diagnosis TYPE1 TYPE2 MODY LADA MIDD DIDMOAD ? Variable Faces of Diabetes Mellitus
  • 14. Type 1 diabetes mellitus Usually onset before age of 40. In USA, peak incidence is around 14 years old. Onset of symptoms may be abrupt, with thirst, excessive urination, increased appetite and weight loss developing over a several-day period. In some cases, the disease is heralded by the appearance of DKA during and intercurrent illness or following surgery.
  • 15. Type 2 Diabetes Mellitus Usually starts in middle age or older. Symptoms begin more gradually than in type 1 diabetes, and diagnosis is frequently made when an asymptomatic person is found to have an elevated plasma glucose on routine lab. Exam..
  • 16. Type 1 vs. Type 2 Type 1 Type 2 Age of onset Childhood, young adult Adulthood, elder people Body cells Responsive to insulin Resistant to insulin Autoantibodies Positive Negative Body fatness Low to average High Endogenous insulin Little or none Normal or too much Pancreatic function Beta cells not functional Beta cell normal Severity of symptoms Severe; liable to DKA Mild; few or none, not liable to DKA Insulin shots? Yes, indispensable Not during early and middle stage Drugs? Not solely Yes
  • 17.  
  • 18. Maturity-onset diabetes of the young (MODY) 45 33 22 12 16 17 10 INS OHA OHA DIET DIET DIET INS Classical MODY-criteria: 1. Two patients diagnosed with diabetes before the age 25 years. 2. Autosomal dominant inheritance of diabetes (  3 generations) Note: Yellow figures indicating ages at on-set.
  • 19. History of MODY genes MODY2 GCK MODY1 Linkage to chr20 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 MODY2 Linkage to chr7 MODY3 Linkage to chr12 MODY3 HNF-1  MODY1 HNF-4  MODY5 HNF-1  MODY4 IPF1
  • 20.  
  • 21. Severe insulin resistance syndrome Insulin signaling associated mutation Lypodystrophy syndrome linked mutation Other gene IR gene AKT2 gene BSCL FPLD MAD CaR gene AGPAT2 gene Seipin gene LMNA PPARγ gene LMNA ZMPSTE24 gene
  • 22.
  • 23. Sequencing of IR exon20 Black Arrow : P1174W Green Arrow : P1178P Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
  • 24. Weng J. Clin Endocrinol (Oxf). 2009 Nov; 71(5):659-65. Epub 2009 Jan 19.
  • 25. HGPS, RD the “most” complicated and lethal type of laminopathies HGPS RD Hum Mol Genet, 2004, 13: 2493-2503. N Engl Med, 2008,358: 552-555.
  • 26.
  • 27. Gestational Diabetes Mellitus ◆ Definition: Carbohydrates intolerance of variable severity with onset or first recognition during pregnancy ◆ Screening: American Diabetic Association(ADA) Recommend screening all pregnant women at 24-26 wks using 50g oral glucose test with 1 hour blood glucose value of 140mg or more as an indication for standard oral glucose tolerance test. No stipulations as to the time of last meal.
  • 28. Clinical manifestation The manifestations of symptomatic diabetes mellitus vary from patient to patient. Most often medical help is sought because of symptoms related to hyperglycemia: polyuria, polydipsia, polyphagia.
  • 29. But, the first event may be an acute metabolic decompensation resulting in diabetic coma. More occasionally, the initial expression can be a degenerative complication such as neuropathy in the absence of symptomatic hyperglycemia.
  • 30.
  • 31. Increased coagulability Platelet hypersensitivity Increased blood viscosity Impaired microvascular flow Increased microvascular pressure and flow Microvascular sclerosis Limitation of maximum perfusion Failure of autoregulation Raised capillary pressure Tissue damage Hypothesis for Diabetic Microangiopathy
  • 32.
  • 34.
  • 35.
  • 36.
  • 37. Foot ulceration Charcot arthropathy Diabetic Foot
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44. LDL-c mmol/L <2.5 2.5-4.4 >4.5 ★ According to UKPDS data . Targets for Diabetic Control Good Moderate Poor FPG mmol/L 4.4-6.1 ≤ 7.0 >7.0 PBS mmol/L 4.4-8.0 ≤ 10.0 >10.0 HbA1c ★ % <6.2 6.2-8.0 >8.0 BMI Kg/m 2 M<25 F<24 M<27 F<26 M ≥ 27 F ≥ 26 T ch mmol/L <4.5 ≥ 4.5 6.0 HDL-c mmol/L >1.1 1.1-0.9 <0.9 TG mmol/L <1.5 <2.2 ≥ 2.2
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50. Exercise Guidelines ※ Monitor BG before and after exercise. ※ Avoid exercise if BG >250 mg/dl, ketones present. ※ Use caution with exercise if BG>300 mg/dl, without ketones. ※ Eat CHO if BG < 100 mg/dl ※ If exercise is planned for just after a meal, consider reducing the short acting insulin that covers that meal. ※ If exercise is planned for 3-4 hours after a meal, consider reducing the long-acting insulin. ※ For unplanned exercise, consider adding carbohydrate. ※ Consume CHO before, during, or after exercise to prevent hypoglycemia. ※ Always keep CHO foods readily available during exercise.
  • 52.
  • 53. Sulfonylurea Activates Insulin Secretion Small figure shows the site of action.
  • 54.
  • 55.
  • 56. Biguanides (Metformin) Mode of action: ◇ reduces hepatic glucose production ◇ decreased intestinal absorption of glucose ◇ increases peripheral utalisation of glucose in muscle & fat tissue ◇ decreased insulin requirements for glucose disposal
  • 57. Precautions: ● chronic renal or cardiac failure ● hepatic impairment ● elderly ● excessive alcohol intake Side effects: ◆ gastrointestinal disturbances ◆ metallic taste ◆ malabsorption of B12 Administer: with or after meals
  • 58.
  • 59.
  • 60.
  • 61. Insulin preparations and time of reaching peak and duration
  • 62. Lipoatrophy due to long term injection of ‘impure’ insulin preparations.
  • 63. Novopen Inhaled insulin Insulin pump
  • 64.
  • 65. Diabetic Ketoacidosis Presentation Physical examination Laboratory results Polyuria, polydipsia Nausea, vomiting Diarrhea, abd. Pain Evolution for a few days Stupor or coma in Loss of skin turgor Kussmaul breathing Acetone odor Cerebral edema PH <7.3, HCO 3 <15 Eq/L Glucose > 250 mg/dl Elevated anion gap High serum ketones High uric acid Normal osmolality
  • 66.
  • 67. Treatment of DKA – IV fluid Normal saline 1 liter/hr until not orthostatic hypotensive, then NS at 500 ml/hr Electrolytes every 2 hrs initially, then every 4 hours Glucose <250 mg/dl, change to Dextrose with 1:4 regular insulin at 250-500 ml/hr When anion gap normal, bicarbonate >15 mEq/L, taking PO fluid, give meal and SC insulin
  • 68. Treatment of DKA – Insulin IV insulin at 5-10 u/hr in adult, 0.1 u/kg/hr in child Check glucose hourly, if no change in 2 hrs double the insulin infusion Glucose <250 mg/dl, slow insulin to 2-4 u/hr Discontinue IV insulin 2-3 hrs after SC insulin dose
  • 69. Treatment of DKA – Potassium Potassium repletion if initial K is normal or low at 10-40 mEq/hr Check potassium every 2- 4 hrs Replete total body potassium stores over 2- 3 days
  • 70. Treatment of DKA – Bicarbonate, Phosphorus Bicarbonate replacement if pH less than 6.90 Check phosphorus 12 hrs into treatment. Replace if < 1 mEq/L